Galderma, a leading global dermatology company, is headquartered in the United States and operates extensively across Europe, Asia, and Latin America. Founded in 1981, Galderma has established itself as a pioneer in the field of medical and aesthetic dermatology, focusing on innovative solutions for skin health. The company is renowned for its core products, including the Restylane® range of dermal fillers and the Sculptra® aesthetic treatment, which are distinguished by their unique formulations and proven efficacy. Galderma's commitment to research and development has positioned it as a trusted name in the industry, with a strong market presence and notable achievements in advancing dermatological care. With a focus on enhancing skin health and beauty, Galderma continues to lead the way in dermatological innovation.
How does Galderma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Galderma's score of 37 is higher than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Galderma, headquartered in the US, currently does not have specific carbon emissions data available for the most recent year, as indicated by the absence of reported figures. The company is a current subsidiary of Galderma Laboratories, L.P., and emissions data may be cascaded from its parent organisation, Galderma Group AG, at a cascade level of three. However, no specific emissions figures or reduction targets have been disclosed. In terms of climate commitments, Galderma has not outlined any specific reduction initiatives or targets, such as those aligned with the Science Based Targets initiative (SBTi). The lack of publicly available data on emissions and reduction strategies suggests that the company may still be in the early stages of formalising its climate action plans. As the industry increasingly prioritises sustainability, Galderma's future commitments and performance in carbon emissions will be crucial for aligning with global climate goals.
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 9,800,000 | 0,000,000 |
| Scope 2 | 4,200,000 | 000,000 |
| Scope 3 | - | 000,000,000 |
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Galderma has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

